Effect of Shugan Jianpi Jiedu Prescription Medicated Serum on Proliferation， Migration and Invasion of Triple-negative Breast Cancer MDA-MB-231 Cells Based on PI3K/Akt/mTOR Signaling Pathway
10.13422/j.cnki.syfjx.20211592
- VernacularTitle:基于PI3K/Akt/mTOR信号通路探讨疏肝健脾解毒方含药血清对三阴乳腺癌MDA-MB-231细胞增殖、迁移和侵袭的影响
- Author:
Lin-pei LI
1
;
Zhen ZHANG
1
;
Bo PAN
2
;
Pu-hua ZENG
2
;
Zheng-ping BAI
1
Author Information
1. Hunan University of Chinese Medicine，Changsha 410208，China
2. The Affiliated Hospital of Hunan Academy of Chinese Medicine，Changsha 410006，China
- Publication Type:Research Article
- Keywords:
Shugan Jianpi Jiedu prescription;
triple-negative breast cancer;
MDA-MB-231 cell;
migration;
invasion;
phosphoinositide 3-kinase （PI3K）/protein kinase B （Akt）/mechanistic target of rapamycin （mTOR） signaling pathway
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2021;27(15):22-28
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the efficacy and mechanism of Shugan Jianpi Jiedu prescription （SJJ） in the treatment of triple-negative breast cancer through in vitro cell experiments. Method:The following groups were set up in this study： a normal serum group，a pirarubicin group，and low-，medium-， and high-dose SJJ-medicated serum groups. Twenty SD rats were randomly divided into four groups and administered with SJJ solution （16.8，8.2，4.05 g·kg-1） and normal saline （equal volume） according to the body surface area to prepare serum. MDA-MB-231 cells were treated separately. The proliferation， migration and invasion of MDA-MB-231 cells were detected by the cell counting kit-8（CCK-8），wound healing assay and transwell cell invasion assay. The phosphoinositide 3-kinase （PI3K），protein kinase B （Akt）， and mechanistic target of rapamycin （mTOR） protein expression levels in MDA-MB-231 cells were tested by the Western blot. Result:The cell proliferation in the three different doses of medicated serum groups and the pirarubicin positive control group was significantly inhibited as compared with that in the normal serum group（P<0.01），and there was no statistical difference for this between the medium/high dose medicated serum group and the pirarubicin positive control group.The wound healing in the SJJ-medicated serum groups and the pirarubicin group was slowed down as compared with that in the normal serum group （P<0.01），and the effect in the SJJ-medicated serum groups was weaker than that in the pirarubicin group （P<0.05，P<0.01）. The number of cells invading the lower transwell chamber was decreased as compared with that in the normal serum group （P<0.01），and there was no statistical difference between the medium-/high-dose SJJ-medicated serum groups and the pirarubicin group. Western blot results showed that 48 h after treatment，the PI3K，Akt， and mTOR expression levels in the cells of SJJ-medicated serum groups and the pirarubicin group were lower than those of the normal serum group（P<0.01）. Conclusion:The SJJ-medicated serum could inhibit the proliferation， migration and invasion of MDA-MB-231 cells presumedly by down-regulating the protein expression levels in the PI3K/Akt/mTOR signaling pathway.
